This inventor holds 1 USPTO granted patent. Top assignee: Boehringer Ingelheim International Gmbh. Active years: 2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023
Title: Sven Bahrenburg: Innovator in Biomolecule Formulations
Introduction
Sven Bahrenburg is a notable inventor based in Biberach, Germany. He has made significant contributions to the field of biomolecule formulations, particularly in the pharmaceutical industry. His innovative work focuses on improving the preparation processes for concentrated liquid formulations containing biomolecules.
Latest Patents
Sven Bahrenburg holds a patent for a "Process for the preparation of concentrated liquid formulations containing biomolecules." This patent describes an improved multi-step process that includes ultrafiltration and diafiltration techniques. The process allows for the creation of highly concentrated formulations, particularly proteins, intended for both pharmaceutical and non-pharmaceutical uses. The method effectively reduces unwanted excipients to very low levels, enhancing the quality of the final product.
Career Highlights
Bahrenburg is associated with Boehringer Ingelheim International GmbH, a leading global pharmaceutical company. His work at the company has been instrumental in advancing the field of biomolecule formulations. With a focus on innovation, he has contributed to the development of processes that improve the efficacy and safety of pharmaceutical products.
Collaborations
Sven Bahrenburg has collaborated with notable colleagues such as Patrick Garidel and Torsten Schultz-Fademrecht. These collaborations have fostered a productive environment for innovation and have led to advancements in the preparation of biomolecule formulations.
Conclusion
Sven Bahrenburg's contributions to the field of biomolecule formulations highlight his role as an innovator in the pharmaceutical industry. His patented processes are paving the way for improved formulations that benefit both pharmaceutical and non-pharmaceutical applications.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
